8:00 am Digital Networking Room Opens

8:25 am Chair’s Opening Remarks

• Satu Juhila Project Leader / Early Clinical Development Oncology, Orion Pharma

Mobilizing Novel Drugs Against the Hippo Pathway to Achieve Effective & Sustained Inhibition of TEAD

8:30 am Developing Effective Covalent Inhibitors Against TEAD as Candidates for Cancer Therapy

• Wanjin Hong Chief Business Development Officer, Biomedical Research Council (BMRC) at A*STAR

9:00 am Preclinical Aspects of HM100385 as a Novel & Non-Covalent YAP/TAZ-TEAD Inhibitor: Therapeutic Potential for Hippo-Pathway Altered Cancers

• Seung Hyun Jung Team Leader, Targeted Oncology Research Team, Hanmi Pharma

9:15 am Revealing Pre-Clinical Findings for TYK 1054 to Target the Hippo/TEAD Pathway

• Shengli Dong Executive Director for Biology, TYK Medicines

9:45 am Advancing a pan-TEAD PPI Inhibitor of the YAP/TEAD Complex to Tackle Mesothelioma Through Protein Liquid-Liquid Phase Separation

• Jidong Zhu Chief executive officer and Co-Founder, Etern bioPharma

10:15 am Morning Break & Virtual Networking

Predicting Clinical Patient Sensitivity for Hippo-Targeted Drugs Using Fit-For-Purpose Pre- Clinical Models to Improve Patient Selection

10:45 am Preclinical Approaches for Predicting Sensitivity to YAP/TAZ-TEAD Inhibition in Cancer

• John Lamar Associate Professor, Albany Medical Center

11:15 am Panel Discussion: How Can We Use Pre-Clinical Models to Accelerate the Translation of Hippo-Targeted Drugs Towards the Clinic?

• Zhi Liang Chu Founder, Chief Executive Officer & Chief scientific officer, Crossignal Therapeutics
• John Lamar Associate Professor, Albany Medical Center
• Satu Juhila Project Leader / Early Clinical Development Oncology, Orion Pharma
• Carsten Hansen Reader, Institute for Regeneration & Repair, University of Edinburgh

12:00 pm Pre-Clinical Mesothelioma Platform to Evaluate Hippo Pathway Targeting Compounds

• Carsten Hansen Reader, Institute for Regeneration & Repair, University of Edinburgh

12:30 pm Lunch Break & Virtual Networking